Chronic Obstructive Pulmonary Disease Treatment Market 2018 -2026

Chronic Obstructive Pulmonary Disease Treatment Market (Drug Class: Combination, Bronchodilators, Corticosteroids, Phosphodiesterase Type 4 Inhibitors, Mucokinetics, and Others; Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 -2026

Chronic Obstructive Pulmonary Disease Treatment Market - Snapshot

The global chronic obstructive pulmonary disease (COPD) treatment market is driven by increase in the number of COPD cases, rise in FDA approvals, and launch of several products in the U.S. Moreover, increase in the geriatric population and rise in expenditure on pharmaceuticals in emerging countries are the other factors contributing to the growth of the market. However, patent expiry of branded products and availability of generic equivalents and alternative treatment options are anticipated to restrain the global market. 

chronic obstructive pulmonary disease treatment market

Based on drug class, the global chronic obstructive pulmonary disease treatment market has been segmented into combination, bronchodilators, corticosteroids, phosphodiesterase type 4 inhibitors, mucokinetics, and others. The combination segment has been classified into long acting muscarinic antagonist & inhaled corticosteroids (LAMA-ICS), long acting beta agonist & inhaled corticosteroids (LABA-ICS), triple therapy, and others. The bronchodilators segment has been divided into long acting beta agonist (LABA), short acting beta agonist (SABA), and long acting muscarinic antagonist (LAMA). The combination segment is projected to account for major share of the market by 2026 due to increase in number of physicians prescribing combination therapy and surge in the number of drugs available for COPD treatment. The bronchodilators segment is anticipated to grow at a steady pace owing to increase in the adoption of long acting muscarinic antagonist (LAMA) drugs. In terms of distribution channel, the market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The retail pharmacies segment is expected to expand at the fastest CAGR due to surge in the number of patients preferring retail pharmacies. The online pharmacies segment is likely to be driven by rise in awareness about these pharmacies among the general population. 

Based on region, the global chronic obstructive pulmonary disease (COPD) treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for the largest share of the global market in 2017. Presence of established pharmaceutical companies, increase in adoption of new drugs launched in the market, and focus on launch of new products through R&D are anticipated to drive the market in the region during the forecast period. 

The chronic obstructive pulmonary disease (COPD) treatment market in Europe is driven by increase in R&D expenditure and launch of new products. In November 2018, GlaxoSmithKline plc and Innoviva, Inc. received authorization from the European Commission for expanded use for once-daily Trelegy Ellipta, first single inhaler triple therapy indicated for COPD patients who were not adequately treated with dual bronchodilation. 

Rise in prevalence of COPD, high environmental pollution, increase in the geriatric population, and growth of the pharmaceutical industry are anticipated to fuel the growth of the chronic obstructive pulmonary disease (COPD) treatment market in Asia Pacific. An article published in the International Journal of Pulmonary and Respiratory Sciences stated that COPD is the third leading cause of death in India. 

The chronic obstructive pulmonary disease (COPD) treatment market in Latin America and Middle East & Africa is expected to be driven by increase in awareness about the diagnosis and treatment of COPD, rise in the number of government initiatives to spread awareness and importance about its treatment, and surge in the number of specialty care centers for respiratory care in various countries in the Middle East. Additionally, GCC Countries such as the UAE and Saudi Arabia present significant opportunities in the market due to strengthening health care system and availability of quality care in hospitals. 

Major players operating in the global chronic obstructive pulmonary disease (COPD) treatment market include AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., GlaxoSmithKline plc, Novartis AG, CHIESI Farmaceutici S.p.A., Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd), Teva Pharmaceutical Industries Ltd., Mylan N.V., and Orion Corporation. 

The global chronic obstructive pulmonary disease treatment market has been segmented as below:

Drug Class

 

  • Combination
    • Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
    • Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
    • Triple Therapy
    • Others
  • Bronchodilators
    • Long Acting Beta Agonist (LABA)
    • Short Acting Beta Agonist (SABA)
    • Long Acting Muscarinic Antagonist (LAMA)
  • Corticosteroids
    • Phosphodiesterase Type 4 Inhibitors
    • Mucokinetics
    • Others

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global COPD Treatment Market

    4. Market Overview
         4.1. Introduction
         4.2. Overview
         4.3. Market Dynamics
                4.3.1. Drivers
                4.3.2. Restraints
                4.3.3. Opportunities
         4.4. Global COPD Treatment Market Analysis and Forecast, 2016–2026

    5. Key Insights
         5.1. Innovative Solutions for COPD Treatment
         5.2. Pipeline Analysis

    6. Global COPD Treatment Market Analysis and Forecast, by Drug Class 
         6.1. Introduction & Definition
         6.2. Key Findings / Developments
         6.3. Market Value Forecast, by Drug Class, 2016–2026
                6.3.1. Combination 
                         6.3.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
                         6.3.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
                         6.3.1.3. Triple Therapy
                         6.3.1.4. Others
                6.3.2. Corticosteroids
                6.3.3. Bronchodilators
                         6.3.3.1. Long Acting Beta Agonist (LABA)
                         6.3.3.2. Short Acting Beta Agonist (SABA)
                         6.3.3.3. Long Acting Muscarinic Antagonist (LAMA)
                6.3.4. Phosphodiesterase Type 4 Inhibitors
                6.3.5. Mucokinetics
                6.3.6. Others
         6.4. Market Attractiveness, by Drug Class 

    7. Global COPD Treatment Market Analysis and Forecast, by Distribution Channel 
         7.1. Introduction & Definition
         7.2. Key Findings / Developments
         7.3. Market Value Forecast, by Distribution Channel, 2016–2026
                7.3.1. Hospital Pharmacies
                7.3.2. Retail Pharmacies
                7.3.3. Online Pharmacies
         7.4. Market Attractiveness, by Distribution Channel 

    8. Global COPD Treatment Market Analysis and Forecast, by Region
         8.1. Key Findings
         8.2. Market Value Forecast, by Region
                8.2.1. North America 
                8.2.2. Europe 
                8.2.3. Asia Pacific 
                8.2.4. Latin America 
                8.2.5. Middle East & Africa 
         8.3. Market Attractiveness By Region

    9. North America COPD Treatment Market Analysis and Forecast
         9.1. Introduction
                9.1.1. Key Findings
         9.2. Market Value Forecast, by Drug Class, 2016–2026
                9.2.1. Combination 
                         9.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
                         9.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
                         9.2.1.3. Triple Therapy
                         9.2.1.4. Others
                9.2.2. Corticosteroids
                9.2.3. Bronchodilators
                         9.2.3.1. Long Acting Beta Agonist (LABA)
                         9.2.3.2. Short Acting Beta Agonist (SABA)
                         9.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
                9.2.4. Phosphodiesterase Type 4 Inhibitors
                9.2.5. Mucokinetics
                9.2.6. Others
         9.3. Market Value Forecast, by Distribution Channel, 2016–2026
                9.3.1. Hospital Pharmacies
                9.3.2. Retail Pharmacies
                9.3.3. Online Pharmacies
         9.4. Market Value Forecast, by Country, 2016–2026
                9.4.1. U.S.
                9.4.2. Canada
         9.5. Market Attractiveness Analysis 
                9.5.1. By Drug Class 
                9.5.2. By Distribution Channel 
                9.5.3. By Country

    10. Europe COPD Treatment Market Analysis and Forecast
         10.1. Introduction
                10.1.1. Key Findings
         10.2. Market Value Forecast, by Drug Class, 2016–2026
                10.2.1. Combination 
                         10.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
                         10.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
                         10.2.1.3. Triple Therapy
                         10.2.1.4. Others
                10.2.2. Corticosteroids
                10.2.3. Bronchodilators
                         10.2.3.1. Long Acting Beta Agonist (LABA)
                         10.2.3.2. Short Acting Beta Agonist (SABA)
                         10.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
                10.2.4. Phosphodiesterase Type 4 Inhibitors
                10.2.5. Mucokinetics
                10.2.6. Others
         10.3. Market Value Forecast, by Distribution Channel, 2016–2026
                10.3.1. Hospital Pharmacies
                10.3.2. Retail Pharmacies
                10.3.3. Online Pharmacies
         10.4. Market Value Forecast, by Country/Sub-region, 2016–2026
                10.4.1. Germany
                10.4.2. U.K.
                10.4.3. France
                10.4.4. Spain
                10.4.5. Italy
                10.4.6. Rest of Europe
         10.5. Market Attractiveness Analysis 
                10.5.1. By Drug Class 
                10.5.2. By Distribution Channel 
                10.5.3. By Country/Sub-region

    11. Asia Pacific COPD Treatment Market Analysis and Forecast
         11.1. Introduction
                11.1.1. Key Findings
         11.2. Market Value Forecast, by Drug Class, 2016–2026
                11.2.1. Combination 
                         11.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
                         11.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
                         11.2.1.3. Triple Therapy
                         11.2.1.4. Others
                11.2.2. Corticosteroids
                11.2.3. Bronchodilators
                         11.2.3.1. Long Acting Beta Agonist (LABA)
                         11.2.3.2. Short Acting Beta Agonist (SABA)
                         11.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
                11.2.4. Phosphodiesterase Type 4 Inhibitors
                11.2.5. Mucokinetics
                11.2.6. Others
         11.3. Market Value Forecast, by Distribution Channel, 2016–2026
                11.3.1. Hospital Pharmacies
                11.3.2. Retail Pharmacies
                11.3.3. Online Pharmacies
         11.4. Market Value Forecast, by Country/Sub-region, 2016–2026
                11.4.1. China
                11.4.2. Japan
                11.4.3. India
                11.4.4. Australia & New Zealand
                11.4.5. Rest of Asia Pacific
         11.5. Market Attractiveness Analysis 
                11.5.1. By Drug Class 
                11.5.2. By Distribution Channel 
                11.5.3. By Country/Sub-region

    12. Latin America COPD Treatment Market Analysis and Forecast
         12.1. Introduction
                12.1.1. Key Findings
         12.2. Market Value Forecast, by Drug Class, 2016–2026
                12.2.1. Combination 
                         12.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
                         12.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
                         12.2.1.3. Triple Therapy
                         12.2.1.4. Others
                12.2.2. Corticosteroids
                12.2.3. Bronchodilators
                         12.2.3.1. Long Acting Beta Agonist (LABA)
                         12.2.3.2. Short Acting Beta Agonist (SABA)
                         12.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
                12.2.4. Phosphodiesterase Type 4 Inhibitors
                12.2.5. Mucokinetics
                12.2.6. Others
         12.3. Market Value Forecast, by Distribution Channel, 2016–2026
                12.3.1. Hospital Pharmacies
                12.3.2. Retail Pharmacies
                12.3.3. Online Pharmacies
         12.4. Market Value Forecast, by Country/Sub-region, 2016–2026
                12.4.1. Brazil
                12.4.2. Mexico
                12.4.3. Rest of Latin America
         12.5. Market Attractiveness Analysis 
                12.5.1. By Drug Class 
                12.5.2. By Distribution Channel 
                12.5.3. By Country/Sub-region

    13. Middle East & Africa COPD Treatment Market Analysis and Forecast
         13.1. Introduction
                13.1.1. Key Findings
         13.2. Market Value Forecast, by Drug Class, 2016–2026
                13.2.1. Combination 
                         13.2.1.1. Long Acting Muscarinic Antagonist & Inhaled Corticosteroids (LAMA-ICS)
                         13.2.1.2. Long Acting Beta Agonist & Inhaled Corticosteroids (LABA-ICS)
                         13.2.1.3. Triple Therapy
                         13.2.1.4. Others
                13.2.2. Corticosteroids
                13.2.3. Bronchodilators
                         13.2.3.1. Long Acting Beta Agonist (LABA)
                         13.2.3.2. Short Acting Beta Agonist (SABA)
                         13.2.3.3. Long Acting Muscarinic Antagonist (LAMA)
                13.2.4. Phosphodiesterase Type 4 Inhibitors
                13.2.5. Mucokinetics
                13.2.6. Others
         13.3. Market Value Forecast, by Distribution Channel, 2016–2026
                13.3.1. Hospital Pharmacies
                13.3.2. Retail Pharmacies
                13.3.3. Online Pharmacies
         13.4. Market Value Forecast, by Country/Sub-region, 2016–2026
                13.4.1. GCC Countries
                13.4.2. South Africa
                13.4.3. Rest of Middle East & Africa
         13.5. Market Attractiveness Analysis 
                13.5.1. By Drug Class 
                13.5.2. By Distribution Channel 
                13.5.3. By Country/Sub-region

    14. Competition Landscape
         14.1. Market Player - Competition Matrix (By Tier and Size of companies)
         14.2. Market Share Analysis, by Company, 2017
         14.3. Company Profiles
                14.3.1. AstraZeneca
                14.3.2. Boehringer Ingelheim Pharmaceuticals, Inc.
                14.3.3. GlaxoSmithKline plc
                14.3.4. Novartis AG
                14.3.5. Teva Pharmaceutical Industries Ltd.
                14.3.6. Sunovion Pharmaceuticals, Inc. (Sumitomo Dainippon Pharma Co., Ltd.) 
                14.3.7. CHIESI Farmaceutici S.p.A.
                14.3.8. Orion Corporation 
                14.3.9. Mylan N.V.

    List of Tables

    Table 01 Pipeline Analysis 
    Table 02 Pipeline Analysis 
    Table 03 Pipeline Analysis 
    Table 04 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 05 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
    Table 06 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
    Table 07 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 08 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Region, 2016–2026
    Table 09  North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 10 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
    Table 11 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
    Table 12 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 13 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country, 2016–2026
    Table 14 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 15 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
    Table 16 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
    Table 17 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 18 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 19 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 20 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
    Table 21 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
    Table 22 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 23 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 24 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 25  Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
    Table 26 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
    Table 27 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 28 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
    Table 29 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Drug Class, 2016–2026
    Table 30 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Combination Therapy, 2016–2026
    Table 31 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Bronchodilators, 2016–2026
    Table 32 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Distribution Channel, 2016–2026
    Table 33 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016–2026

    List of Figures

    Figure 01 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Distribution, by Region, 2017 and 2026
    Figure 02 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Revenue (US$ Mn), by Drug Class, 2017
    Figure 03 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 04 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 05 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Combination, 2016–2026
    Figure 06 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Bronchodilators, 2016–2026
    Figure 07 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Corticosteroids, 2016–2026
    Figure 08 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Phosphodiesterase Type 4 Inhibitors, 2016–2026
    Figure 09 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Mucokinetics, 2016–2026
    Figure 10 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) and Y-o-Y Growth, by Others, 2016–2026
    Figure 11 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 12 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 13 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Hospital Pharmacies, 2016–2026
    Figure 14 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Independent Pharmacies, 2016–2026
    Figure 15 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value (US$ Mn) and Y-o-Y Growth (%) Forecast, by Online Pharmacies, 2016–2026
    Figure 16 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 17 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Region, 2017 and 2026
    Figure 18 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Region, 2018–2026
    Figure 19 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 20 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 21 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 22 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 23 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018 - 2026
    Figure 24 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country, 2017 and 2026
    Figure 25 North America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country, 2018–2026
    Figure 26 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 27 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 28 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 29 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 30 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018 - 2026
    Figure 31 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 32 Europe Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 33 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 34 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 35 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 36 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 37 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 38 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 39 Asia Pacific Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 40 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 41 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 42 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 43 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 44 Latin America Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 45 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2016–2026
    Figure 46 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Drug Class, 2017 and 2026
    Figure 47 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Drug Class, 2018–2026
    Figure 48 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
    Figure 49 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Distribution Channel, 2018–2026
    Figure 50 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
    Figure 51 Middle East & Africa Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Attractiveness Analysis, by Country/Sub-region, 2018–2026
    Figure 52 Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market Share, by Company, 2017
    Figure 53 AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 54 AstraZeneca R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 55 AstraZeneca Breakdown of Net Sales (%), by Region, 2017
    Figure 56 AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2017
    Figure 57 Boehringer Ingelheim International GmbH , Human Pharmaceuticals Business Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 58 Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 59 Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2017
    Figure 60 Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 61 GlaxoSmithKline plc Respiratory Business Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 62 GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 63 GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2017
    Figure 64 GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 65 Novartis AG COPD Portfolio Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 66 Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 67 Novartis AG Breakdown of Net Sales (%), by Country, 2017
    Figure 68 Novartis AG Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 69 Teva Pharmaceutical Industries Ltd Respiratory Medicine Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 70 Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 71 Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Region, 2017
    Figure 72 Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 73 Sumitomo Dainippon Pharma Co., Ltd Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 74 Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 75 Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Region, 2017
    Figure 76 Sumitomo Dainippon Pharma Co., Ltd Breakdown of Net Sales (%), by Product Segment, 2017
    Figure 77 CHIESI Farmaceutici S.p.A. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 78 CHIESI Farmaceutici S.p.A. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 79 CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Region, 2017
    Figure 80 CHIESI Farmaceutici S.p.A. Breakdown of Net Sales (%), by Therapeutics Area, 2017
    Figure 81 Orion Corporation Pharmaceuticals Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 82 Orion Corporation R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2017
    Figure 83 Orion Corporation Breakdown of Net Sales (%), by Country, 2017
    Figure 84 Orion Corporation Breakdown of Net Sales (%), by Business Segment, 2017
    Figure 85 Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 86 Mylan N.V. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2015–2017
    Figure 87 Mylan N.V. Breakdown of Net Sales (%), by Region, 2017

Copyright © Transparency Market Research, Inc. All Rights reserved